US Patent Issued to Regeneron Pharmaceuticals on May 6 for "Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 receptor (IL4R) antibody" (New York, Washington, Maryland Inventors)

ALEXANDRIA, Va., June 10 -- United States Patent no. 12,291,571, issued on May 6, was assigned to Regeneron Pharmaceuticals Inc. (Tarrytown, N.Y.).

"Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 receptor (IL4R) antibody" was invented by Ana Kostic (New York), Ludmila Kelly (Silver Spring, Md.), Xia Liu (Hopewell Junction, N.Y.), Brendan J. Classon (Seattle) and Allen Radin (New York).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides methods for treating, preventing or reducing the severity of eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising ...